Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis
· cision pr newswire
AI Briefing
- Celosia Therapeutics announces Phase 1b clinical trial of CTx1000 for ALS
- CTx1000 aims to clear TDP-43 protein, a driver of the disease
- First patient dosed in trial of gene therapy for ALS
Advertisement